|
FOLGENDES HABE ICH BEI Hoovers gefunden, Analysteneinschätzung von Robertson Stephens: "Yesterday GPC announced second quarter results. Excluding one-off charges relating, among other things, to the Mitotix acquisition, the numbers were broadly in line with our expectations," said Williams. "We continue to expect GPC to sign further deals based on its core genomics service business, including one or two fee-for- service deals this year and a large EUR 30-50 million deal during the next 12 months. We maintain our Buy rating." moremoney |
|
| aus der Diskussion: | Auch die Amis lieben GPC Biotech |
| Autor (Datum des Eintrages): | moremoney! (29.08.00 08:22:44) |
| Beitrag: | 1 von 4 (ID:1683533) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |